Screening and application of drug-eluting stents in patients with cardiovascular diseases

Wu Jin

doi:10.3969/j.issn.2095-4344.2016.38.022

Abstract：BACKGROUND:Drug-eluting stents have achieved better treatment outcomes, but late stent thrombosis shakes its status. With the development of drug-eluting stents, loaded drugs are the key to reduce stent thrombosis. OBJECTIVE:To analyze the screening and application of drug-eluting stents. METHODS:A computer-based search was performed for literatures published from 2010 to 2016 in databases of PubMed and WanFang using the keywords of“drug eluting stents;rapamycin (sirolimus);paclitaxel;heparin;zotarolimus;everolimus”in English and Chinese, respectively. According to inclusion and exclusion criteria, 30 eligible literatures were included for analysis. RESULTS AND CONCLUISON:An ideal drug-eluting stent can selectively inhibit vascular smooth muscle and is expected to be anti-coagulated, but makes no effects on vascular endothelial cel s or promoting the cel proliferation. Most of the loaded drugs are antithrombotic and anti-proliferative drugs, among which, rapamycin-eluting and paclitaxel-eluting stents are extensively used. Regardless of delaying the proliferation of vascular endothelial cel s and increasing the thrombosis risk, most of drug-eluting stents are stil loaded with these two drugs, and only few stents loaded with rapamycin derivatives, such as everolimus, zotarolimus, tacrolimus and pimecrolimus. Current research focuses on developing a stent with rapid drug releasing and anti-proliferative capacity. Meanwhile, the combination of drugs and biphasic releasing are another novel idea.